VX-880 not checked
Vertex Pharmaceuticals · Formerly known as STx-02
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Type 1 Diabetes, Kidney Transplant, Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
- Main trialPhase 3
- “This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.”In the company’s words, NCT06832410 on ClinicalTrials.gov
- Other names
- Zimislecel · Formerly known as STx-02 · Biological/Vaccine
Other drugs for Type 1 Diabetes
- TirzepatideEli Lilly · Phase 3
- Insulin icodecNovo Nordisk · Phase 3
- CadisegliatinvTv Therapeutics · Phase 3
- Stem Cell Educator therapyYong Zhao, MD, PhD · Phase 3
- VX-017Vertex Pharmaceuticals · Phase 3
- TeplizumabSanofi · Phase 3
Coming up1
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 17 Sep 2026 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | |
| Phase 3Recruiting | 31 Dec 2027 | A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026